

****New release September 2009****

DiseaseINFOPACK: *Streptococcus dysgalactiae* (SDSE) (CAT: VADIP016)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	Comprehensive review/analysis of <i>S. dysgalactiae</i> (SDSE) disease trends/dynamics
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Streptococcal infections</i>
Product (if applicable)	:	CAT No: VADIP016, published September 2009

Background

Streptococcus dysgalactiae subsp. *Equisimilis* (SDSE) is usually a beta-hemolytic commensal organism found in the human throat and skin which can cause a spectrum of human diseases similar to *Streptococcus pyogenes* or Group A Streptococcus (GAS) (1). These diseases include superficial skin infections, pharyngitis and life threatening conditions such as Streptococcal toxic shock syndrome (STSS).

SDSE may express group A, group C or group G Lancefield antigens, but generally SDSE expressing group C antigen (GGS) is the most common form of human disease. Unlike invasive disease due to GAS, SDSE infections are not notifiable in most countries with only the UK (Health Protection Agency) reporting bacteremia split by subtype.

This expert **DiseaseINFOPACK** report is a comprehensive up-to-date review of current literature regarding SDSE across EU, US and "Rest of World regions". It will allow the reader to quickly grasp current understanding regarding SDSE and help ascertain disease dynamics/trends relative to other important causes of invasive and non-invasive infections in immunocompromised groups. The report may guide novel antibiotic development and/or passive immunotherapeutics.

1) Rolston KV. Group G streptococcal infections. Arch Intern Med. 1986 May;146(5):857-8

PRODUCT CONTENTS:

Published September 2009 (CAT No: VADIP016)

Executive summary
The pathogen
Pathogenesis
Spectrum of disease
Spectrum of disease: Pharyngitis
Spectrum of disease: Invasive disease
Host response
Risk groups
Transmission
Treatment
Prevention and control
Surveillance
Epidemiology: Incidence
Epidemiology: US
Epidemiology: Canada
Epidemiology: UK
Epidemiology: Germany
Epidemiology: Finland
Epidemiology: Denmark
Epidemiology: Japan
Epidemiology: Taiwan
Epidemiology: summary
Mortality
Bibliography
About VacZine Analytics
Disclaimer

PAGES: ~52 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form

PROJECT METHODOLOGY:

VacZine Analytics has conducted a comprehensive secondary research to review all available information regarding SDSE in major Western (US + EU) and SE Asia markets. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc.

PRODUCT PRICE:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:


- o USD \$4895.00/ GBP £3265.00 (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 15% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. Rolston KV. Group G streptococcal infections. *Arch Intern Med.* 1986 May;146(5):857-8
2. Kuusi M et al. An outbreak of *Streptococcus equi* subspecies *zooepidemicus* associated with consumption of fresh goat cheese. *BMC Infect Dis.* 2006 Feb 27;6:36
3. Ural O et al. *Streptococcus zooepidemicus* meningitis and bacteraemia. *Scand J Infect Dis.* 2003;35(3):206-7.
4. Carragoso A et al. [Spinal epidural abscess due to group C *Streptococcus*]. *Acta Reumatol Port.* 2007 Jul-Sep;32(3):287-97.
5. Elsayed S et al. *Streptococcus equi* subspecies *equi* (Lancefield group C) meningitis in a child. *Clin Microbiol Infect.* 2003 Aug;9(8):869-72
6. Jacobs JA et al. *Streptococcus anginosus*, *Streptococcus constellatus* and *Streptococcus intermedius*. *Am J Clin Pathol.* 1995 Nov;104(5):547-53.
7. Broyles LN et al. Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. *Clin Infect Dis.* 2009 Mar 15;48(6):706-12.
8. Clarridge JE 3rd et al. Genotypic and phenotypic characterization of "Streptococcus milleri" group isolates. *J Clin Microbiol.* 1999 Nov;37(11):3681-7.
9. Clarridge JE 3rd et al. *Streptococcus intermedius*, *Streptococcus constellatus*, and *Streptococcus anginosus* are of different clinical importance and are not equally associated with abscess. *Clin Infect Dis.* 2001 May 15;32(10):1511-5.
10. Kobashi Y et al. Clinical analysis of cases of empyema due to *Streptococcus milleri* group. *Jpn J Infect Dis.* 2008 Nov;61(6):484-6.
11. Albertí S et al. Survey of emm-like gene sequences from pharyngeal isolates of group C and group G streptococci collected in Spain. *J Clin Microbiol.* 2005
12. Schnitzler N et al. M or M-like protein gene polymorphisms in human group G streptococci. *J Clin Microbiol.* 1995 Feb;33(2):356-63.
13. Davies, MR et al. Virulence profiling of *Streptococcus dysgalactiae* subspecies *equisimilis*. *Clin. Infect. Dis.* 44, 1442–1454.
14. Kalia A et al. Presence of streptococcal pyrogenic exotoxin A and C genes in human isolates of group G streptococci. *FEMS Microbiol Lett.* 2003 Feb 28;219(2):291-5.
15. Igwe EI et al. Identification of superantigen genes *speM*, *ssa*, and *smeZ* in invasive strains of beta-hemolytic group C and G. *FEMS Microbiol Lett.* 2003 Dec 12;229(2):259-64.
16. Cleary, PP et al. Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci. *Infect. Immun.* 59:2305-2310
17. Towers RJ et al. Fibronectin-binding protein gene recombination and horizontal transfer between group A and G streptococci. *J Clin Microbiol.* 2004 Nov;42(11):5357-61
18. Ahmad Y et al. Genetic relationships deduced from emm and multilocus sequence typing of invasive *Streptococcus dysgalactiae* subsp. *equisimilis* and *S. canis* recovered from isolates collected in the United States. *J Clin Microbiol.* 2009 Jul;47(7):2046-54.
19. Davies MR et al. Phage 3396 from a *Streptococcus dysgalactiae* subsp. *equisimilis* pathovar may have its origins in *streptococcus pyogenes*. *J Bacteriol.* 2007 Apr;189(7):2646-52.
20. Siljander T et al. Acute bacterial, nonnecrotizing cellulitis in Finland: microbiological findings. *Clin Infect Dis.* 2008 Mar 15;46(6):855-61.
21. González Terán B et al. Acute bacterial arthritis caused by group C streptococci. *Semin Arthritis Rheum.* 2001 Aug;31(1):43-51.
22. Menon T et al. Bacterial endocarditis due to Group C streptococcus. *J Postgrad Med.* 2008 Jan-Mar;54(1):64-5.
23. Erdem G et al. A case report and literature review of group C streptococcal pneumonia. *Hawaii Med J.* 2009 May;68(4):85-7.
24. Matsui D et al. [A case of bacterial pneumonia caused by *Streptococcus dysgalactiae* subsp. *equisimilis*, showing patchy consolidations resembling organizing pneumonia]. *Nihon Kokyuki Gakkai Zasshi.* 2007 Jan;45(1):36-42.
25. Lindbaek M et al. Clinical symptoms and signs in sore throat patients with large colony variant beta-haemolytic streptococci groups C or G versus group A. *Br J Gen Pract.* 2005 Aug;55(517):615-9.
26. Villar HE et al. [High prevalence of beta hemolytic streptococci isolated from throat swabs in Buenos Aires]. *Medicina (B Aires).* 2005;65(4):311-4.
27. Gerber MA et al. Community-wide outbreak of group G streptococcal pharyngitis. *Pediatrics* 1991; 87: 598–603.
28. Shah M et al. Severe acute pharyngitis caused by group C streptococcus. *J Gen Intern Med.* 2007 Feb;22(2):272-4.
29. Zaoutis T et al. The role of group C and group G streptococci in acute pharyngitis in children. *Clin Microbiol Infect.* 2004 Jan;10(1):37-40.
30. Peñalba Citores AC et al. [Incidence of streptococcal pharyngitis]. *An Pediatr (Barc).* 2007 Sep;67(3):220-4.
31. Zwart S et al. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. *BMJ.* 2000 Jan 15;320(7228):150-4.
32. Llor C et al. [Validation of a rapid antigenic test in the diagnosis of pharyngitis caused by group a beta-haemolytic *Streptococcus*]. *Aten Primaria.* 2008 Oct;40(10):489-94.

33. Steer AC et al. Prospective surveillance of streptococcal sore throat in a tropical country. *Pediatr Infect Dis J.* 2009 Jun;28(6):477-82.
34. Lloyd CA et al. Pharyngeal carriage of group A streptococci in school children in Chennai. *Indian J Med Res.* 2006 Aug;124(2):195-8.
35. Levantia, Z. et al. Group A, C and G beta hemolytic streptococci from children with pharyngitis, during 2003-2007. XVII Lancefield International Symposium on Streptococci and Streptococcal Diseases, 22-26 June 2008, Porto Heli, Greece.
36. Palmieri C et al. erm(A)-mediated macrolide resistance and ability to invade human respiratory cells in a *Streptococcus dysgalactiae* subspecies *equisimilis* pharyngeal isolate. *J Antimicrob Chemother.* 2007 Dec;60(6):1405-6.
37. Stelter K et al. [Lethal end of a group C streptococcal necrotizing fasciitis in a healthy female] *Laryngorhinootologie.* 2006 Mar;85(3):197-200.
38. Horas U et al. [Necrotizing fasciitis caused by group G streptococci]. *Orthopade.* 2008 Jun;37(6):592-4.
39. Misawa Y et al. [A case of severe necrotizing cellulitis caused by group G *Streptococcus dysgalactiae* subsp. *equisimilis*]. *Kansenshogaku Zasshi.* 2006 Jul;80(4):436-9.
40. Shigemitsu K et al. [Toxic shock-like syndrome in elderly adult caused by group G streptococci]. *Nippon Naika Gakkai Zasshi.* 2008 Oct 10;97(10):2555-7.
41. Marinella MA. Group C streptococcal sepsis complicating Fournier gangrene. *South Med J.* 2005 Sep;98(9):921-3.
42. Powell C et al. Toxic shock syndrome in a neonate. *Pediatr Infect Dis J.* 2007 Aug;26(8):759-60.
43. Ikebe T et al. Surveillance of severe invasive group-G streptococcal infections and molecular typing of the isolates in Japan. *Epidemiol Infect.* 2004 Jan;132(1):145-9.
44. Humar D et al. Streptolysin S and necrotising infections produced by group G streptococcus. *Lancet.* 2002 Jan 12;359(9301):124-9.
45. Pyogenic and non-pyogenic streptococcal bacteraemias, England, Wales and Northern Ireland: 2007 Annual Update. Available at: <http://www.hpa.org.uk/>. Accessed: September 2009
46. Björnsdóttir S et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. *Clin Infect Dis.* 2005 Nov 15;41(10):1416-22.
47. Rantala S et al. Clinical presentations and epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study. *Clin Microbiol Infect.* 2009 Mar;15(3):286-8.
48. Savini V et al. Beta-lactam failure in treatment of two group G *Streptococcus dysgalactiae* subsp. *equisimilis* Pharyngitis patients. *J Clin Microbiol.* 2008 Feb;46(2):814-6.
49. Rubio-Lopez, V. et al. Groups C and G beta-hemolytic *Streptococcus* spp. In Spain. XVII Lancefield International Symposium on Streptococci and Streptococcal Diseases, 22-26 June 2008, Porto Heli, Greece.
50. Table 1 Laboratory reports of streptococcal bacteraemia, England, Wales, and Northern Ireland: 2003-2007. Available at: <http://www.hpa.org.uk/>. Accessed: September 2009
51. German Federal Health Monitoring. Available at: <http://www.gbe-bund.de> Accessed: September 2009
52. Ekelund K et al. Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. *Clin Microbiol Infect.* 2005 Jul;11(7):569-76.
53. Laupland KB et al. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. *Clin Microbiol Infect.* 2006 Mar;12(3):224-30.
54. Infectious Disease Surveillance Center. Infectious Agents Surveillance Report, 2005-2009. Available at: <http://idsc.nih.gov.jp/>. Accessed: August 2009.
55. Wong SS et al. Increase in group G streptococcal infections in a community hospital, New York, USA. *Emerg Infect Dis.* 2009 Jun;15(6):991-3.
56. Health Protection Report. Pyogenic and non-pyogenic streptococcal bacteraemias, England, Wales and Northern Ireland. Volume 2 Number 47, 21 November 2008
57. Lewthwaite P et al. Group G streptococcal bacteraemia: an opportunistic infection associated with immune senescence. *Scand J Infect Dis.* 2002;34(2):83-7.
58. Ubukata K et al. [Large-scale questionnaire surveillance concerning invasive infections with group C and G streptococci]. *Kansenshogaku Zasshi.* 2006 Sep;80(5):480-7.
59. Hasegawa T et al. Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan. *Microbes Infect.* 2004 Oct;6(12):1073-7.
60. Liao CH et al. Bacteremia caused by group G Streptococci, Taiwan. *Emerg Infect Dis.* 2008 May;14(5):837-40.
61. Bair MJ et al. Necrotizing fasciitis in southeast Taiwan: clinical features, microbiology, and prognosis. *Int J Infect Dis.* 2009 Mar;13(2):255-60.
62. Rantala S et al. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. *J Infect.* 2009 Apr;58(4):266-72.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at www.vaczine-analytics.com

**VacZine Analytics
Of Assay Advantage Ltd**

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009



VacZine Analytics[®]

Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** info@vacZine-analytics.com

